(HLN) Haleon - Ratings and Ratios
Toothpaste, Vitamins, Cold-Relief, Pain-Relief, Antacids
Dividends
| Dividend Yield | 1.85% |
| Yield on Cost 5y | 2.46% |
| Yield CAGR 5y | 50.96% |
| Payout Consistency | 100.0% |
| Payout Ratio | 48.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 20.4% |
| Value at Risk 5%th | 33.9% |
| Relative Tail Risk | 1.24% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -6.79 |
| CAGR/Max DD | 0.39 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.499 |
| Beta | 0.227 |
| Beta Downside | 0.051 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.11% |
| Mean DD | 7.06% |
| Median DD | 6.64% |
Description: HLN Haleon December 03, 2025
Haleon plc (NYSE:HLN) is a global consumer-health company that develops, manufactures, and sells a broad portfolio of over-the-counter (OTC) products across North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Its brands span oral care (Sensodyne, Aquafresh, Parodontax), vitamins and supplements (Centrum, Emergen-C, Caltrate), respiratory relief (Otrivine, Theraflu, Flonase), pain and inflammation (Voltaren, Advil, Panadol), and digestive health (TUMS, ENO, Fenistil). The firm was formerly DRVW 2022 plc and rebranded as Haleon in February 2022; it traces its roots back to 1715 and is headquartered in Weybridge, United Kingdom.
In FY 2023 Haleon reported net sales of approximately $3.4 billion, with a year-over-year organic growth rate of 5.2% driven largely by strong demand for its vitamin-mineral and oral-care lines. The companys adjusted EBITDA margin held steady around 22%, reflecting continued pricing power despite inflationary input costs. Cash flow from operations exceeded $1.0 billion, supporting a dividend yield of roughly 2.5% and a share-repurchase program announced in Q3 2024.
Key sector drivers include an aging global population that raises demand for chronic-condition supplements, and a sustained shift toward self-care that boosts OTC sales. However, macro-level risks such as currency volatility (especially GBP/EUR exposure) and potential regulatory tightening on health-claim labeling could pressure margins. Base-rate analysis of the consumer-health market suggests a long-term CAGR of 4–5% through 2030, with North America remaining the largest revenue contributor.
For a deeper, data-rich dive into Haleon’s valuation dynamics, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 661.1m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -2.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5.63% (prev -8.12%; Δ 2.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 3.33b > Net Income 1.52b (YES >=105%, WARN >=100%) |
| Net Debt (7.78b) to EBITDA (2.66b) ratio: 2.93 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.53b) change vs 12m ago -1.61% (target <= -2.0% for YES) |
| Gross Margin 62.94% (prev 60.68%; Δ 2.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.79% (prev 33.71%; Δ 0.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.22 (EBITDA TTM 2.66b / Interest Expense TTM 330.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.21
| (A) -0.02 = (Total Current Assets 4.14b - Total Current Liabilities 4.76b) / Total Assets 31.83b |
| (B) 0.86 = Retained Earnings (Balance) 27.27b / Total Assets 31.83b |
| warn (B) unusual magnitude: 0.86 — check mapping/units |
| (C) 0.07 = EBIT TTM 2.38b / Avg Total Assets 32.61b |
| (D) 1.01 = Book Value of Equity 15.94b / Total Liabilities 15.83b |
| Total Rating: 4.21 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.20
| 1. Piotroski 5.50pt |
| 2. FCF Yield 2.28% |
| 3. FCF Margin 8.45% |
| 4. Debt/Equity 0.53 |
| 5. Debt/Ebitda 2.93 |
| 6. ROIC - WACC (= 1.58)% |
| 7. RoE 9.40% |
| 8. Rev. Trend 34.37% |
| 9. EPS Trend 8.12% |
What is the price of HLN shares?
Over the past week, the price has changed by -2.66%, over one month by +2.26%, over three months by -2.86% and over the past year by -0.36%.
Is HLN a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.6 | 22% |
| Analysts Target Price | 11.6 | 22% |
| ValueRay Target Price | 10.2 | 7% |
HLN Fundamental Data Overview November 26, 2025
P/E Trailing = 22.3182
P/E Forward = 18.4502
P/S = 3.9892
P/B = 2.0627
P/EG = 2.8845
Beta = 0.23
Revenue TTM = 11.02b GBP
EBIT TTM = 2.38b GBP
EBITDA TTM = 2.66b GBP
Long Term Debt = 7.58b GBP (from longTermDebt, last quarter)
Short Term Debt = 813.0m GBP (from shortTermDebt, last quarter)
Debt = 8.45b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.78b GBP (from netDebt column, last quarter)
Enterprise Value = 40.75b GBP (32.97b + Debt 8.45b - CCE 676.0m)
Interest Coverage Ratio = 7.22 (Ebit TTM 2.38b / Interest Expense TTM 330.0m)
FCF Yield = 2.28% (FCF TTM 931.0m / Enterprise Value 40.75b)
FCF Margin = 8.45% (FCF TTM 931.0m / Revenue TTM 11.02b)
Net Margin = 13.81% (Net Income TTM 1.52b / Revenue TTM 11.02b)
Gross Margin = 62.94% ((Revenue TTM 11.02b - Cost of Revenue TTM 4.08b) / Revenue TTM)
Gross Margin QoQ = 64.51% (prev 64.51%)
Tobins Q-Ratio = 1.28 (Enterprise Value 40.75b / Total Assets 31.83b)
Interest Expense / Debt = 0.76% (Interest Expense 64.5m / Debt 8.45b)
Taxrate = 24.37% (131.0m / 537.5m)
NOPAT = 1.80b (EBIT 2.38b * (1 - 24.37%))
Current Ratio = 0.87 (Total Current Assets 4.14b / Total Current Liabilities 4.76b)
Debt / Equity = 0.53 (Debt 8.45b / totalStockholderEquity, last quarter 15.94b)
Debt / EBITDA = 2.93 (Net Debt 7.78b / EBITDA 2.66b)
Debt / FCF = 8.35 (Net Debt 7.78b / FCF TTM 931.0m)
Total Stockholder Equity = 16.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.78% (Net Income 1.52b / Total Assets 31.83b)
RoE = 9.40% (Net Income TTM 1.52b / Total Stockholder Equity 16.19b)
RoCE = 10.03% (EBIT 2.38b / Capital Employed (Equity 16.19b + L.T.Debt 7.58b))
RoIC = 7.15% (NOPAT 1.80b / Invested Capital 25.20b)
WACC = 5.57% (E(32.97b)/V(41.43b) * Re(6.85%) + D(8.45b)/V(41.43b) * Rd(0.76%) * (1-Tc(0.24)))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.00%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈1.26b ; Y1≈830.0m ; Y5≈379.6m
Fair Price DCF = 1.68 (DCF Value 7.46b / Shares Outstanding 4.45b; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 8.12 | EPS CAGR: 101.1% | SUE: -0.02 | # QB: 0
Revenue Correlation: 34.37 | Revenue CAGR: 2.58% | SUE: 0.10 | # QB: 0
EPS next Year (2026-12-31): EPS=0.54 | Chg30d=-0.001 | Revisions Net=-2 | Growth EPS=+9.8% | Growth Revenue=+4.8%
Additional Sources for HLN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle